vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

Stock Information for 22nd Century Group Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About 22nd Century Group Inc

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE
vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update
vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference
vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.